Related Experiment Video
Updated: Aug 31, 2025
Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue
Published on: November 30, 2018
Therapeutic Targeting of Histone Deacetylation to Prevent Alzheimer's Disease
Sophia Chacko1, Warren Ladiges1
1Department of Comparative Medicine, School of Medicine, University of Washington, USA.
Abstract:
Efforts to find disease-modifying treatments for Alzheimer's disease (AD) have been largely unsuccessful. The relative lack of progress and the age-related incidence of AD suggest that modulation of aging per se may be a useful alternative treatment approach. Therapeutics aimed at preventing or reversing aging should be effective in preventing or reversing dementia and the pathology associated with progressive AD. Epigenetic dysregulation of neuronal gene expression occurs with age, propagating deficits in cellular homeostasis. Regulators of epigenetic processes, such as histone deacetylases (HDACs), are well documented and may represent promising therapeutic targets. HDAC activity becomes dysregulated with age and in AD. An intriguing concept is that HDAC inhibition effectively forestalls AD pathology measured more broadly, addressing the notion that rectifying homeostatic gene expression may be the critical step in ameliorating AD pathogenesis at the earliest stage of disease initiation. HDAC inhibitors target several pathways associated with aging and AD neuropathology including loss of synaptic function, mitochondrial dysfunction, increased oxidative stress, and decreased autophagy activity. Since transcriptional levels of numerous genes are shown to decrease with increasing age, a recovery of their transcriptional activity through HDAC inhibition could prevent or delay age-associated declines in neurological function and provide pathways for treating AD.
Insights
Targeting the aging process itself may offer a new strategy for Alzheimer's disease (AD) treatment. Inhibiting histone deacetylases (HDACs) could reverse age-related epigenetic changes and prevent AD progression.
Area of Science:
- Neuroscience
- Gerontology
- Pharmacology
Background:
- Alzheimer's disease (AD) treatments have seen limited success.
- Aging is a primary risk factor for AD, suggesting aging modulation as a therapeutic strategy.
- Epigenetic dysregulation, particularly involving histone deacetylases (HDACs), is implicated in age-related cognitive decline and AD.
Purpose of the Study:
- To explore the potential of targeting aging processes, specifically epigenetic regulation via HDAC inhibition, as a novel therapeutic approach for Alzheimer's disease.
- To investigate if modulating aging through HDAC inhibition can prevent or reverse AD-related dementia and neuropathology.
Main Methods:
- The study reviews existing literature on aging, epigenetics, HDACs, and Alzheimer's disease.
- It analyzes the role of HDACs in age-related gene expression changes and cellular homeostasis.
- The potential impact of HDAC inhibitors on pathways affected by aging and AD is discussed.
Main Results:
- HDAC activity is dysregulated with age and in AD.
- HDAC inhibitors show potential to counteract multiple aging and AD-related pathways, including synaptic dysfunction, mitochondrial issues, oxidative stress, and impaired autophagy.
- Restoring transcriptional activity via HDAC inhibition may prevent or delay age-associated neurological decline.
Conclusions:
- Modulating the aging process, particularly through HDAC inhibition, presents a promising alternative strategy for treating Alzheimer's disease.
- HDAC inhibitors may offer a way to rectify age-related epigenetic deficits, thereby ameliorating AD pathogenesis.
- This approach could prevent or delay cognitive decline by restoring gene expression crucial for neurological function.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
02:25Spreading of Chromatin Modifications
Writers
The writer...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...